프라수그렐 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "프라수그렐" in Korean language version.

refsWebsite

Global rank Korean rank

13doi.org

2^nd place

3^rd place

13nih.gov

4^th place

6semanticscholar.org

11^th place

310^th place

3web.archive.org

1^st place

1health.kr

low place

2,285^th place

1europa.eu

68^th place

145^th place

1archive.org

6^th place

18^th place

1lilly.com

low place

1fda.gov

447^th place

433^rd place

1unizar.es

low place

archive.org (Global: 6^th place; Korean: 18^th place)

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S 외 (November 2007). “Prasugrel versus clopidogrel in patients with acute coronary syndromes”. 《The New England Journal of Medicine》 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Baker WL, White CM (2009). “Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes”. 《American Journal of Cardiovascular Drugs》 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S 외 (November 2007). “Prasugrel versus clopidogrel in patients with acute coronary syndromes”. 《The New England Journal of Medicine》 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA 외 (August 2016). “National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016”. 《The Medical Journal of Australia》 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F 외 (October 2014). “Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis”. 《BMJ》 349 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF 외 (September 2013). “Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes”. 《The New England Journal of Medicine》 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.
John J, Koshy SK (2012). “Current oral antiplatelets: focus update on prasugrel”. 《Journal of the American Board of Family Medicine》 25 (3): 343–349. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J 외 (2018년 11월 19일). “PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis”. 《Frontiers in Physiology》 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y 외 (September 2009). “Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials”. 《Lancet》 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G 외 (September 2016). “Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial”. 《The American Journal of Medicine》 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A 외 (April 2006). “Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450”. 《Drug Metabolism and Disposition》 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). “Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog”. 《Drug Metabolism and Disposition》 44 (3): 409–416. doi:10.1124/dmd.115.068221. PMID 26718653.
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS 외 (January 2007). “A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation”. 《American Heart Journal》 153 (1): 66.e9–66.16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD 외 (December 2007). “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial”. 《Circulation》 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“European Public Assessment Report for Efient” (PDF). EMA. 2009. 2018년 3월 19일에 원본 문서 (PDF)에서 보존된 문서. 2024년 5월 27일에 확인함.

fda.gov (Global: 447^th place; Korean: 433^rd place)

“Effient (prasugrel hydrochloride) Prescribing Information”. U.S. Food and Drug Administration (FDA). September 2011. 2017년 1월 18일에 원본 문서에서 보존된 문서. 2019년 12월 16일에 확인함.

health.kr (Global: low place; Korean: 2,285^th place)

“에피언트정5mg”. 《약학정보원》. 2024년 5월 27일에 확인함.

lilly.com (Global: low place; Korean: low place)

pi.lilly.com

“Efient (prasugrel) tablets: Highlights of prescribing information” (PDF). Eli Lilly. 2011. 2012년 1월 31일에 원본 문서 (PDF)에서 보존된 문서.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Baker WL, White CM (2009). “Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes”. 《American Journal of Cardiovascular Drugs》 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S 외 (November 2007). “Prasugrel versus clopidogrel in patients with acute coronary syndromes”. 《The New England Journal of Medicine》 357 (20): 2001–2015. doi:10.1056/NEJMoa0706482. PMID 17982182.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA 외 (August 2016). “National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016”. 《The Medical Journal of Australia》 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F 외 (October 2014). “Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis”. 《BMJ》 349 (aug06 2): g6269. doi:10.1136/bmj.g6269. PMC 4208629. PMID 25954988.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF 외 (September 2013). “Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes”. 《The New England Journal of Medicine》 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.
John J, Koshy SK (2012). “Current oral antiplatelets: focus update on prasugrel”. 《Journal of the American Board of Family Medicine》 25 (3): 343–349. doi:10.3122/jabfm.2012.03.100270. PMID 22570398.
Demcsák A, Lantos T, Bálint ER, Hartmann P, Vincze Á, Bajor J 외 (2018년 11월 19일). “PPIs Are Not Responsible for Elevating Cardiovascular Risk in Patients on Clopidogrel-A Systematic Review and Meta-Analysis”. 《Frontiers in Physiology》 9: 1550. doi:10.3389/fphys.2018.01550. PMC 6252380. PMID 30510515.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y 외 (September 2009). “Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials”. 《Lancet》 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G 외 (September 2016). “Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial”. 《The American Journal of Medicine》 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A 외 (April 2006). “Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450”. 《Drug Metabolism and Disposition》 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.
Kurokawa T, Fukami T, Yoshida T, Nakajima M (March 2016). “Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog”. 《Drug Metabolism and Disposition》 44 (3): 409–416. doi:10.1124/dmd.115.068221. PMID 26718653.
Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS 외 (January 2007). “A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation”. 《American Heart Journal》 153 (1): 66.e9–66.16. doi:10.1016/j.ahj.2006.10.010. PMID 17174640.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD 외 (December 2007). “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial”. 《Circulation》 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Baker WL, White CM (2009). “Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes”. 《American Journal of Cardiovascular Drugs》 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.
Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA 외 (August 2016). “National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016”. 《The Medical Journal of Australia》 205 (3): 128–133. doi:10.5694/mja16.00368. PMID 27465769. S2CID 13014429.
Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF 외 (September 2013). “Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes”. 《The New England Journal of Medicine》 369 (11): 999–1010. doi:10.1056/NEJMoa1308075. PMID 23991622. S2CID 205095981.
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y 외 (September 2009). “Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials”. 《Lancet》 374 (9694): 989–997. doi:10.1016/S0140-6736(09)61525-7. PMID 19726078. S2CID 205956050.
Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A 외 (April 2006). “Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450”. 《Drug Metabolism and Disposition》 34 (4): 600–607. doi:10.1124/dmd.105.007989. PMID 16415119. S2CID 1698598.
Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD 외 (December 2007). “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial”. 《Circulation》 116 (25): 2923–2932. doi:10.1161/CIRCULATIONAHA.107.740324. PMID 18056526. S2CID 8226182.

unizar.es (Global: low place; Korean: low place)

zaguan.unizar.es

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G 외 (September 2016). “Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial”. 《The American Journal of Medicine》 129 (9): 1002–1005. doi:10.1016/j.amjmed.2016.03.042. PMID 27143321.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“European Public Assessment Report for Efient” (PDF). EMA. 2009. 2018년 3월 19일에 원본 문서 (PDF)에서 보존된 문서. 2024년 5월 27일에 확인함.
“Efient (prasugrel) tablets: Highlights of prescribing information” (PDF). Eli Lilly. 2011. 2012년 1월 31일에 원본 문서 (PDF)에서 보존된 문서.
“Effient (prasugrel hydrochloride) Prescribing Information”. U.S. Food and Drug Administration (FDA). September 2011. 2017년 1월 18일에 원본 문서에서 보존된 문서. 2019년 12월 16일에 확인함.

프라수그렐 (Korean Wikipedia)

archive.org (Global: 6th place; Korean: 18th place)

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

europa.eu (Global: 68th place; Korean: 145th place)

ema.europa.eu

fda.gov (Global: 447th place; Korean: 433rd place)

health.kr (Global: low place; Korean: 2,285th place)

lilly.com (Global: low place; Korean: low place)

pi.lilly.com

nih.gov (Global: 4th place; Korean: 4th place)

ncbi.nlm.nih.gov

semanticscholar.org (Global: 11th place; Korean: 310th place)

api.semanticscholar.org

unizar.es (Global: low place; Korean: low place)

zaguan.unizar.es

web.archive.org (Global: 1st place; Korean: 1st place)

archive.org (Global: 6^th place; Korean: 18^th place)

doi.org (Global: 2^nd place; Korean: 3^rd place)

europa.eu (Global: 68^th place; Korean: 145^th place)

fda.gov (Global: 447^th place; Korean: 433^rd place)

health.kr (Global: low place; Korean: 2,285^th place)

nih.gov (Global: 4^th place; Korean: 4^th place)

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

web.archive.org (Global: 1^st place; Korean: 1^st place)